# EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/egfr-inhibition-reverses-resistance-to-lenvatinib-in-hepatocellular-carcinoma/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Xiaoping He,Yohko Hikiba,Yoshimasa Suzuki,Yoshinori Nakamori,Yushi Kanemaru,Makoto Sugimori,Takeshi Sato,Akito Nozaki,Makoto Chuma,Shin Maeda |
| Citations | 59 |
| DOI | 10.1038/s41598-022-12076-w |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://www.nature.com/articles/s41598-022-12076-w.pdf |
| OpenAlex ID | https://openalex.org/W4280514910 |
| PMID | 35568782 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Yoshimasa Suzuki](https://scholariq.org/researchers/yoshimasa-suzuki/)

## Paper journal

- [Scientific Reports](https://scholariq.org/journals/scientific-reports/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.